Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $8.3 million.

  • Ligand Pharmaceuticals' Depreciation & Amortization (CF) fell 806.09% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.2 million, marking a year-over-year decrease of 377.17%. This contributed to the annual value of $35.2 million for FY2024, which is 351.03% down from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Depreciation & Amortization (CF) is $8.3 million, which was down 806.09% from $8.5 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $13.7 million during Q1 2022, with a 5-year trough of $8.3 million in Q3 2025.
  • In the last 5 years, Ligand Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $9.5 million in 2023 and averaged $10.5 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Depreciation & Amortization (CF) skyrocketed by 26718.29% in 2021, and later tumbled by 3611.07% in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $13.2 million in 2021, then dropped by 15.45% to $11.1 million in 2022, then fell by 19.93% to $8.9 million in 2023, then decreased by 3.24% to $8.6 million in 2024, then decreased by 4.15% to $8.3 million in 2025.
  • Its Depreciation & Amortization (CF) was $8.3 million in Q3 2025, compared to $8.5 million in Q2 2025 and $8.8 million in Q1 2025.